drugset / Trial / NCT07457190
Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelOther
Summary
This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.
Timeline
- Start
- 2026-03
- Primary completion
- 2026-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buagafuran | Unknown | 30 mg | — |